Rhythm Pharmaceuticals Statistics
Rhythm Pharmaceuticals (1RV) Stock Statistics & Valuation Metrics
Total Valuation
Rhythm Pharmaceuticals has a market cap or net worth of EUR 7.12B. The enterprise value is EUR 6.47B.
- Market Cap
- EUR 7.12B
- Enterprise Value
- EUR 6.47B
Share Statistics
Rhythm Pharmaceuticals has 69,330,910 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 69,330,910
- Owned by Insiders
- 0.77%
- Owned by Institutions
- 52.11%
Financial Efficiency
Rhythm Pharmaceuticals’s return on equity (ROE) is -0.73 and return on invested capital (ROIC) is -51.22%.
- Return on Equity (ROE)
- -0.73
- Return on Assets (ROA)
- -0.41
- Return on Invested Capital (ROIC)
- -51.22%
- Return on Capital Employed (ROCE)
- -0.51
- Revenue Per Employee
- 458.35K
- Profits Per Employee
- -474.73K
- Employee Count
- 414
- Asset Turnover
- 0.40
- Inventory Turnover
- 0.76
Valuation Ratios
The current PE Ratio of Rhythm Pharmaceuticals is -38.68. Rhythm Pharmaceuticals’s PEG ratio is -6.04.
- PE Ratio
- -38.68
- PS Ratio
- 27.70
- PB Ratio
- 38.42
- Price to FCF
- -61.02
- Price to Operating Cash Flow
- -61.48
- PEG Ratio
- -6.04
Income Statement
In the last 12 months, Rhythm Pharmaceuticals had revenue of 189.76M and earned -196.54M in profits. Earnings per share was -3.11.
- Revenue
- 189.76M
- Gross Profit
- 170.26M
- Operating Income
- -192.02M
- Pretax Income
- -196.04M
- Net Income
- -196.54M
- EBITDA
- -174.12M
- Earnings Per Share (EPS)
- -3.11
Cash Flow
In the last 12 months, operating cash flow was -125.97M and capital expenditures -1.45M, giving a free cash flow of -127.43M billion.
- Operating Cash Flow
- -125.97M
- Free Cash Flow
- -127.43M
- Free Cash Flow per Share
- -1.85
Dividends & Yields
Rhythm Pharmaceuticals pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -1.64%
- Earnings Yield
- -2.50%
Stock Price Statistics
- Beta
- 0.26
- 52-Week Price Change
- 23.35%
- 50-Day Moving Average
- 84.45
- 200-Day Moving Average
- 81.78
- Relative Strength Index (RSI)
- 71.85
- Average Volume (3m)
- 42
Important Dates
Rhythm Pharmaceuticals upcoming earnings date is Mar 03, 2027, TBA (Not Confirmed).
- Last Earnings Date
- Nov 03, 2026
- Next Earnings Date
- Mar 03, 2027
- Ex-Dividend Date
- ―
Financial Position
Rhythm Pharmaceuticals as a current ratio of 4.41, with Debt / Equity ratio of 1.48%
- Current Ratio
- 4.41
- Quick Ratio
- 4.16
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 0.29
- Interest Coverage Ratio
- -9.33
Taxes
In the past 12 months, Rhythm Pharmaceuticals has paid 497.00K in taxes.
- Income Tax
- 497.00K
- Effective Tax Rate
- -0.00
Enterprise Valuation
Rhythm Pharmaceuticals EV to EBITDA ratio is -44.66, with an EV/FCF ratio of -60.72.
- EV to Sales
- 27.56
- EV to EBITDA
- -44.66
- EV to Free Cash Flow
- -60.72
- EV to Operating Cash Flow
- -61.42
Balance Sheet
Rhythm Pharmaceuticals has EUR 320.94M in cash and marketable securities with EUR 3.52M in debt, giving a net cash position of EUR 317.43M billion.
- Cash & Marketable Securities
- EUR 320.94M
- Total Debt
- EUR 3.52M
- Net Cash
- EUR 317.43M
- Net Cash Per Share
- EUR 4.58
- Tangible Book Value Per Share
- EUR 2.68
Margins
Gross margin is 88.23%, with operating margin of -66.70%, and net profit margin of -69.03%.
- Gross Margin
- 88.23%
- Operating Margin
- -66.70%
- Pretax Margin
- -68.48%
- Net Profit Margin
- -69.03%
- EBITDA Margin
- -61.70%
- EBIT Margin
- -61.98%
Analyst Forecast
The average price target for Rhythm Pharmaceuticals is EUR 134.20, which is 11.43% higher than the current price. The consensus rating is Strong Buy
- Price Target
- EUR 134.20
- Price Target Upside
- 30.29% Upside
- Analyst Consensus
- Strong Buy
- Analyst Count
- 15
- Revenue Growth Forecast
- 54.12%
- EPS Growth Forecast
- 10.85%
Scores
- Smart Score
- 8
- AI Score
- ―
